NEW YORK, March 7 – After Affymetrix disclosed that its U74 Mouse arrays contained defective sequences, the microarray maker’s shares slid nearly 11 percent Wednesday by midday.

The company’s shares were down $5 15/16, at 50 1/16 in early-afternoon trading on the Nasdaq.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.